AngioDynamics (ANGO) to Release Earnings on Tuesday

AngioDynamics (NASDAQ:ANGO) is projected to announce its Q2 2026 results before the market opens on Tuesday, January 6th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $76.4330 million for the quarter. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, January 6, 2026 at 8:00 AM ET.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The company had revenue of $75.71 million during the quarter, compared to analysts’ expectations of $72.69 million. During the same quarter in the previous year, the business posted ($0.11) earnings per share. The firm’s quarterly revenue was up 12.1% compared to the same quarter last year. On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AngioDynamics Price Performance

Shares of AngioDynamics stock opened at $12.87 on Tuesday. AngioDynamics has a 1 year low of $8.27 and a 1 year high of $13.99. The business has a 50 day moving average price of $12.61 and a 200 day moving average price of $10.91. The company has a market capitalization of $530.24 million, a P/E ratio of -16.50 and a beta of 0.49.

Wall Street Analyst Weigh In

ANGO has been the subject of several analyst reports. Canaccord Genuity Group boosted their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Wall Street Zen downgraded shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.33.

Insider Buying and Selling at AngioDynamics

In other news, SVP Lawrence T. Weiss bought 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 21st. The shares were acquired at an average cost of $11.81 per share, with a total value of $118,100.00. Following the transaction, the senior vice president owned 93,597 shares of the company’s stock, valued at $1,105,380.57. This represents a 11.96% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO James C. Clemmer acquired 10,000 shares of the business’s stock in a transaction dated Thursday, October 9th. The stock was purchased at an average price of $11.15 per share, for a total transaction of $111,500.00. Following the completion of the acquisition, the chief executive officer owned 882,529 shares in the company, valued at approximately $9,840,198.35. This trade represents a 1.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 20,890 shares of company stock valued at $239,532 over the last three months. Corporate insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds and other institutional investors have recently bought and sold shares of ANGO. American Century Companies Inc. lifted its holdings in AngioDynamics by 15.8% during the 2nd quarter. American Century Companies Inc. now owns 96,808 shares of the medical instruments supplier’s stock worth $960,000 after buying an additional 13,217 shares during the last quarter. Rhumbline Advisers raised its position in shares of AngioDynamics by 4.3% during the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after acquiring an additional 2,510 shares in the last quarter. Jane Street Group LLC boosted its holdings in AngioDynamics by 267.1% in the first quarter. Jane Street Group LLC now owns 46,803 shares of the medical instruments supplier’s stock worth $439,000 after purchasing an additional 34,054 shares during the period. Goldman Sachs Group Inc. increased its stake in AngioDynamics by 9.6% during the first quarter. Goldman Sachs Group Inc. now owns 259,226 shares of the medical instruments supplier’s stock valued at $2,434,000 after purchasing an additional 22,658 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of AngioDynamics during the third quarter worth $207,000. 89.43% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.